1 No-Brainer Stock to Buy With $40

Core Viewpoint - Exelixis is positioned as a strong investment opportunity in the biotech sector, particularly due to its successful product Cabometyx and recent legal victories that enhance its market position [1][3]. Company Overview - Exelixis is an oncology-focused biotech company, primarily known for its product Cabometyx, which treats renal cell carcinoma and hepatocellular carcinoma [2]. - Cabometyx is a leading tyrosine kinase inhibitor (TKI) in the treatment of renal cell carcinoma [3]. Financial Performance - In Q2, Cabometyx's revenue increased by 35.6% year over year, reaching $637.2 million, with U.S. revenue accounting for $437.6 million, approximately 69% of Exelixis' total revenue [2]. - The company has demonstrated strong financial performance despite previous threats from generic competition [4]. Legal Developments - Exelixis won a lawsuit against MSN Laboratories, preventing the launch of a generic version of cabozantinib until at least early 2030, which significantly reduces financial risk for the company [3]. Future Prospects - Exelixis is awaiting approval for Cabometyx for treating previously treated pancreatic neuroendocrine tumors and is conducting several additional trials [4]. - The company is developing other promising candidates, including zanzalintinib, which is in phase 3 studies for metastatic colorectal cancer and targets unmet needs in oncology [5]. Investment Appeal - With shares trading under $30, Exelixis is considered an affordable investment with a strong pipeline and steady revenue growth expected through the end of the decade [5].